Understand the source comparison
MGF vs IGF-1 LR3: A Side-by-Side Comparison
The table below summarizes the mechanistic and pharmacological contrasts drawn from the preclinical literature. Every entry describes findings in cell or animal models or in vitro characterization; none should be read as a claim about effects, safety, or use i
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below summarizes the mechanistic and pharmacological contrasts drawn from the preclinical literature. Every entry describes findings in cell or animal models or in vitro characterization; none should be read as a claim about effects, safety, or use in humans.
- Origin
- Endogenous alternative splice variant of the IGF-1 gene, induced by mechanical load/damage
- Wholly synthetic engineered analog of IGF-1
- Structure
- Mature IGF-1 core plus a unique E-domain from a reading-frame shift; research typically uses only the isolated 24-aa C-terminal E-peptide
- 83-aa protein: full IGF-1 with Arg substituted at position 3 plus a 13-aa N-terminal extension
- Primary receptor studied
- Isolated E-peptide effects reported as largely IGF-1R-independent (receptor unidentified); in-vivo E-domain-driven hypertrophy has been reported as IGF-1R-dependent
- Type 1 IGF receptor (IGF-1R), same as native IGF-1
- IGFBP interaction
- Intact variant proposed to bind a distinct muscle-interstitial binding protein; kept unstable/local
- Deliberately reduced IGFBP affinity to evade sequestration
- Duration of action
- Short and transient; expression peaks early then declines within days
- Extended free-ligand availability in vitro; systemic in vivo pharmacokinetics are nuanced
- Spatial scale
- Local — autocrine/paracrine
- Systemic when administered exogenously
- Best-characterized legitimate use
- Research tool for satellite-cell and myoblast biology
- Cell-culture growth supplement (e.g., CHO cells); in-vitro reproductive biology reagent
- Strength of muscle evidence
- Preclinical/in vitro and animal; includes a notable failed independent replication and conflicting in-vivo E-peptide data
- Cell and animal models; little muscle-specific in-vivo characterization published
- Regulatory status
- Not FDA-approved; research reagent
- Not FDA-approved as a drug; research/manufacturing reagent
- For readers comparing dosing and reconstitution conventions used in laboratory handling of these reagents, the site maintains structured reference pages: the MGF vial dosage protocol reference and the IGF-1 LR3 vial dosage protocol reference. These are research-handling references, not usage recommendations.